Petros Grivas, Clinical Director of the GU cancers Program at the University of Washington, shared a post on X by Andrea Necchi, Associate Editor at Journal of Clinical Oncology, adding:
“Congrats Matt Galsky, Andrea Necchi et al. elegant methodology and interesting hypotheses! Kudos for pursuing biomarker analyses in the context of a positive trial!”
Quoting Andrea Necchi‘s post:
“Exploratory biomarker analyses of adjuvant Nivolumab in urothelial carcinoma from CheckMate274 trial are out in Nature Medicine.
- Pre-existing immune infiltration and T-cell infiltration is prognostic and predictive of adj Nivo benefit
- Composite model development is the key to select those pts with high risk features who benefit the most from adj Nivo”
Title: Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial
Authors: Matthew D. Galsky, Dean F. Bajorin, Yoshihiko Tomita, Dingwei Ye, Mads Agerbaek, Deborah Enting, Avivit Peer, Matthew Milowsky, Ko Kobayashi, Marc-Oliver Grimm, Frank Stenner, Justin M. David, Jun Li, Scott D. Chasalow, Federico Nasroulah, Abraham Apfel, Keziban Ünsal-Kaçmaz, Andrea Necchi
You can read the Full Article in the Nature Medicine.
More posts featuring Petros Grivas on OncoDaily.
